Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: An assessment from the ARTEMIS DISK Global Antifungal Surveillance Program

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 2, 2010, Pages 162-171

  Pfaller, Michael A ^a   Diekema, Daniel J ^a   Gibbs, David L ^b   Newell, Vance A ^b   Barton, Richard ^c   Bijie, Hu ^d   Bille, Jacques ^e   Chang, Shan Chwen ^f   da Luz Martins, Maria ^g   Duse, Adriano ^h   Dzierzanowska, Danuta ⁱ   Ellis, David ^j   Finquelievich, Jorge ^k   Gould, Ian ^l   Gur, Deniz ^m   Hoosen, Anwar ⁿ   Lee, Kyungwon ^o   Mallatova, Nada ^p   Mallie, Michele ^q   Peng, NG Kee ^r   Petrikos, George ^s   Santiago, Axel ^t   Trupl, Jan ^u   VanDen Abeele, Ann Marie ^t   Wadula, Jeannette ^v   Zaidi, Mussaret ^w   more..

^a UNIVERSITY OF IOWA   (United States)

^b Giles Scientific Inc   (United States)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g Instituto de Higiena e Medicina Tropical   (Portugal)

^h WITJ University   (South Africa)

ⁱ CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^j WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^k Centro de Micologia   (Argentina)

^l NHS GRAMPIAN   (United Kingdom)

^m HACETTEPE UNIVERSITY   (Turkey)

ⁿ Ga Rankuwa Hospital   (South Africa)

^o Yonsei University College of Medicine   (South Korea)

^p Hospital Ceske Budejovice   (Czech Republic)

^q UNIV MONTPELLIER   (France)

^r UNIVERSITY OF MALAYA   (Malaysia)

^s LAIKO GENERAL HOSPITAL   (Greece)

^t Universitario de Caracas ^*  (Belgium)

^u SYNLAB ACADEMY   (Germany)

^v UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^w Hospital General O'Horan   (Mexico)

more..

Author keywords

Azoles; Candida glabrata; Surveillance

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

AFRICA; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASIA; CANDIDA GLABRATA; CONTROLLED STUDY; DISK DIFFUSION; DRUG SURVEILLANCE PROGRAM; EUROPE; FUNGUS ISOLATION; GENE FREQUENCY; GEOGRAPHICAL VARIATION (SPECIES); MIDDLE EAST; NONHUMAN; NORTH AMERICA; PACIFIC ISLANDS; PRIORITY JOURNAL; QUALITY CONTROL; SOUTH AND CENTRAL AMERICA;

AFRICA; AMERICAS; ANTIFUNGAL AGENTS; ASIA; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; EUROPE; FLUCONAZOLE; GEOGRAPHY; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST; PYRIMIDINES; TRIAZOLES;

EID: 77952743793     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.01.002     Document Type: Article

References (77)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 1997, 24:1122-1128.
2. Alexander B.D., Schell W.A., Miller J.L., Long G.D., Perfect J.R. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005, 80:868-871.
3. Almirante B., Rodriquez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., Mensa J., Sanchez F., Ayats J., Gimenez M., Sabolls P., Fridkin S.K., Morgan J., Rodriguez-Tudela J.L., Warnock D.W., Pahissa A. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 2005, 43:1829-1835. the Barcelona Candidemia Project Study Group.
4. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schonkeyder H.C., Knudsen J.D., Jensen I.M., Bruun B., Christensen J.J., Johansen H.K. Semi-national surveillance of fungaemia in Denmark, 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 2008, 14:487-494.
5. Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J. Antimcirob. Chemother. 2007, 60:459-460.
6. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol. 2002, 40:3489-3492.
7. Baddley J.W., Smith A.M., Moser S.A., Pappas P.G. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital. Diagn. Microbiol. Infect. Dis. 2001, 39:199-201.
8. Baddley J.W., Patel M., Bhavnani S.M., Moser S.A., Andes D.R. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 2008, 52:3022-3028.
9. Bilgen H., Ozek E., Korten V., et al. Treatment of systemic neonatal candidiasis with fluconazole. Infection 1995, 23:394.
10. Boschman C.R., Bodnar U.R., Tornatore M.A., et al. Thirteen-years evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob. Agents Chemother. 1998, 42:734-738.
11. Chen Y.C., Chong S.C., Luh K.T., Hsieh W.C. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother. 2003, 52:71-77.
12. Cheng M.F., Yu K.W., Tant R.B., Fan Y.H., Yang Y.L., Hsieh K.S., Ho M., Lo H.J. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 2004, 48:33-37.
13. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D., Chawea V., Young J., Hadley S. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 2008, 46:1206-1213.
14. Clinical and Laboratory Standards Institute (CLSI) Method for antifungal disk diffusion testing of yeasts; approved standard, M44-A 2004, CLSI, Wayne, PA.
15. Clinical and Laboratory Standards Institute (CLSI) Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement (M44-S2) 2007, CLSI, Wayne, PA.
16. Collins D.C., Eschenauer G.A., Salo S.L., Newton D.W. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemia. J. Clin. Microbiol. 2007, 45:1884-1888.
17. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., Bearden D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 2006, 43:25-31.
18. Garey K.W., Pai M.P., Suda K.J., Turpin R.S., Rege M.D., Mingo D.E., Bearden D.R. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol. Drug Saf. 2007, 16:919-927.
19. Gonzalez G.M., Elizondo M., Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J. Clin. Microbiol. 2008, 46:2902-2905.
20. Guery B.P., Arendrup M.C., Auzinger G., Azoulay E., Sa M.B., Johnson E.M., Muller E., Putensen C., Rotstein C., Sganga G., Verditti M., Crespo R.Z., Kullberg B.J. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009, 36:55-62.
21. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
22. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., Phelan M., Morgan J., Lee-Yang W., Ciblak M.A., Benjamin L.E., Sonza L.T., Huie S., Yeo S.F., Brandt M.E., Warnock D.W. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based surveillance program. J. Clin. Microbiol. 2004, 42:1519-1527.
23. Hedderwick S.A., Wan J.Y., Bradley S.F., Sangeorzan J.A., Terpening M.S., Kauffman C.A. Risk factors for colonization with yeast species in a Veterans Affairs long-term care facility. J. Am. Geriatr. Soc. 1998, 46:849-853.
24. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaci A.J., Marr K.A., Pfaller M.A., Chong C.H., Webster K.M. Clinical characteristics of 2019 patients with candidemia: data from the PATH Alliance Registry. Clin. Infect. Dis. 2009, 48:1695-1703.
25. Hseuh P.R., Teng L.J., Yang P.C., Ho S.W., Luh K.T. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb. Drug Resist. 2002, 8:311-319.
26. Hseuh P.R., Lau Y.J., Chuang Y.C., Wan J.H., Huang W.K., Syr J.M., Yan J.J., Yu K.W., Wu J.J., Ko W.C., Yang Y.C., Liu Y.C., Teng L.J., Lin C.Y., Luh K.T. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 2005, 49:512-517.
27. Klevay M.J., Horn D.L., Neofytos D., Pfaller M.A., Diekema D.J. Initial treatment and outcome of Candida glabrata versus C. albicans bloodstream infection. Diagn. Microbiol. Infect. Dis. 2009, 64:152-157.
28. Laupland K.B., Gregson D.B., Church D.L., Ross T., Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother. 2005, 56:532-537.
29. Lee I., Fishman N.O., Zauotis T.E., Morales K.H., Weiner M.G., Synnestvedt M., Nachamkin I., Lautenbach E. Risk factors for fluconazole-resistant C. glabrata bloodstream infections. Arch. Intern. Med. 2009, 169:379-383.
30. Li L., Redding S., Dongari-Bagtzoglou A. Candida glabrata, an emerging oral opportunistic pathogen. J. Dent. Res. 2007, 86:204-215.
31. Lichtenstein C., Nguyen T.H., Schemon P., Hoppe-Tichy T., Weigland M.A. Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy. Mycoses 2008, 51(Suppl. 1):35-46.
32. Luzzati R., Amalfitano G., Lazzarini L., Soldori F., Bellino S., Solbiatic M., Danzi M.C., Vento S., Todeschini G., Vivenza C., Concia E. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 2000, 19:602-607.
33. Magill S.S., Shields C., Sears C.L., Choti M., Merz W.G. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 2006, 44:529-535.
34. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., Kauffman C. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 2005, 41:975-981.
35. Marchetti O., Bille J., Fluckinger U., Eggimann P., Ruef C., Garbino J., Calandra T., Glauser M.P., Tauber M.G., Pittet D. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 2004, 38:311-320.
36. Marr K.A., Seidel K., White T.C., Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 2000, 181:309-316.
37. Morrell M., Fraser V.J., Kollef M.J. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 2005, 49:3640-3645.
38. Nguyen M.H., Peacock J.E., Morris A.J., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 1996, 100:617-623.
39. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., Lee J. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 2003, 47:3149-3154.
40. Panackal A.A., Gribskov J.L., Staab J.F., Kirby K.A., Rinaldi M., Marr K.A. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 2006, 44:1740-1743.
41. Pappas P.G. The patient with candidemia: treatment choices and algorithms. Curr. Fungal Infect. Rep. 2008, 2:112-119.
42. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., Edwards J.E. Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 2004, 38:161-189. The Infectious Diseases Society of America.
43. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 38:161-189.
44. Parkins M.D., Sabuda D.M., El Sayed S., Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 2007, 60:613-618.
45. Pasqualotto A.C., Zimerman R.A., Alves S.H., Aquino V.R., Branco D., Wiltgen D., do Amaral A., Cechinel R., Colares S.M., da Rocha I.G., Severo L.C., Sukiennik T.C.T. Take control over your fluconazole prescription: the growing important of Candida glabrata as an agent of candidemia in Brazil. Infect. Control. Hosp. Epidemiol. 2008, 29:898-899.
46. Perlroth J., Choi B., Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. 2007, 45:321-346.
47. Pfaller M.A., Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 2004, 10(Suppl. 1):11-23.
48. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007, 20:133-163.
49. Pfaller M.A., Diekema D.J. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 2007, 1:74-92.
50. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D.J. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol. 2003, 41:2176-2179.
51. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D.J. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 to 2002. J. Clin. Microbiol. 2004, 42:3142-3146.
52. Pfaller M.A., Hazen K.C., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D.J. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 2004, 42:3607-3612.
53. Pfaller M.A., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., Diekema D.J. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 2005, 43:5208-5213.
54. Pfaller M.A., Diekema D.J., Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 2006, 19:435-447.
55. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microibol. 2006, 44:819-826.
56. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Meis J.F., Gould I.M., Fu W., Colombo A.L., Rodriquez-Noriega E., the Global Antifungal Surveillance Study Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 2007, 45:1735-1745.
57. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 2008, 46:150-156.
58. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2009, the Global Antifungal Surveillance Goup, submitted.
59. Pfaller M.A., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Kroeger J., Diekema D.J. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States, 2001-2007. J. Clin. Microbiol. 2009, 47:3185-3190.
60. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis. 2009, 65:27-34. ARTEMIS DISK Global Surveillance Group.
61. Poikonen E., Lyytikainen O., Arttila V.J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 2003, 9:352-356.
62. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., Betts R., Wible M., Goldstein B.P., Schranz J., Krause D.S., Walsh T.J. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 2007, 356:2472-2482.
63. Richet H., Roux P., Des Champs C., Esnault Y., Andremont A. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect. 2002, 8:405-412. the French Candidemia Study Group.
64. Riddell J.I.V., Kauffman C.A. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer 2008, 112:2334-2337.
65. Ruan S.Y., Lee L.N., Jerng J.S., Yu C.J., Hsueh P.R. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 2008, 14:136-140.
66. Sandven P., Bevanger L., Digranes A., Houklend H.H., Mannsaker T., Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 2006, 44:1977-1981. the Norwegian Yeast Study Group.
67. Sendid B., Cotteau A., Francois N., D'Haveloose A., Standaert A., Camus D., Poulain D. Candidemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect. Dis. 2006, 6:80-89.
68. Shorr A.F., Lazarus D.R., Sherner J.H., Jackson W.L., Morrel M., Fraser V.J., Kollef M.H. Do clinical features allow for accurate predictions of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit. Care Med. 2007, 35:1077-1083.
69. Spanakis E.K., Aperis G., Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 2006, 43:1060-1068.
70. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 2006, 42:244-251.
71. Tan T.Y., Tan A.L., Tee N.W.S., Ng L.S.Y. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore Hospitals. Ann. Acad. Med. Singapore 2008, 37:835-840.
72. Tortorano A.M., Biraghi E., Astofi A., Ossi C., Tejada M., Farina C., Perin S., Bonaccorso C., Cavanna C., Raballo A., Grossi A. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J. Hosp. Infect. 2002, 51:297-304. the FIMUA Candidemia Study Group.
73. Tortorano A.M., Kibbler C., Peman J., Bernhandt H., Klingspor L., Grillot R. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 2006, 27:359-366.
74. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P., the National Nosocomial Infections Surveillance System Hospitals Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 2002, 35:622-630.
75. Wilson A.G., Micek S.T., Ritchie D.J. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin. Ther. 2005, 27:1228-1237.
76. Xess I., Jain N., Hasan F., Mandal P., Banerjie U. Epidemiology of candidemia in a tertiary care centre of North India: 5-year study. Infection 2007, 35:256-259.
77. Yang Y.L., Chang H.H., Lo H.J., the TSARY Hospitals Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med. Mycol. 2006, 44:237-242.